Seattle Genetics, Astellas ADC posts strong response in bladder combo study at ESMO

As enfortumab vedotin awaits regulatory action to treat advanced bladder cancer, Seattle Genetics and partner Astellas showed impressive combination data for the antibody-drug conjugate that could quickly move the molecule even earlier in the disease.

In the Phase I EV-103 trial of 45

Read the full 427 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE